Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nova Szoka

Obesity Medicine Morgantown, WV Medical Doctor

NPI 1912227083 CMS profile 1311664

1 Medical Center Dr, Morgantown, WV 26506

Open in the dashboard

General payments

$5,775

35 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$2,604,000

2 holdings reported · through program year 2025

Through program year 2025, Nova Szoka of Morgantown, WV is reported in the CMS Open Payments database as having received $5,775 across 35 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $2,604,000 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,806 11
2024 General $2,001 8
2023 General $444 6
2022 General $209 6
2019 General $315 4
2025 Ownership $1,302,000 1
2024 Ownership $1,302,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nova Szoka
  • Obesity Medicine median
  • Middle half of Obesity Medicine
  • National median

In program year 2025, general payments to Nova Szoka were reported at $2,806. Among 72 Obesity Medicine profiles paid that year, the median was $191 and the middle half received between $116 and $2,515.

Show as a table
Year Nova Szoka Obesity Medicine median Middle half National median
2019 $315 $224 $90–$564 $163
2020 $0 $118 $51–$1,043 $114
2021 $0 $195 $98–$1,394 $132
2022 $209 $223 $87–$754 $149
2023 $444 $228 $103–$1,114 $160
2024 $2,001 $150 $83–$471 $164
2025 $2,806 $191 $116–$2,515 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endolumik, Inc. $4,334 13 payments
  2. Ethicon Inc. $715 8 payments
  3. Intuitive Surgical, Inc. $231 8 payments
  4. Davol Inc. $155 1 payment
  5. ReShape Lifesciences Inc. $121 1 payment
  6. Medtronic, Inc. $104 1 payment
  7. Ethicon US, LLC $73 2 payments
  8. Baxter Healthcare $41 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,031 8 payments
  2. Food and Beverage $1,294 22 payments
  3. Consulting Fee $400 4 payments
  4. Entertainment $50 1 payment
Products named General payments · program years 2019–2025
  1. Endolumik Gastric Calibration Tube Bariatric $2,456 8 payments
  2. Endolumik Gastric Calibration Tube Bariatric Surgery $1,878 5 payments
  3. Da Vinci Surgical System $231 8 payments
  4. Phasix Mesh $155 1 payment
  5. ENDO GIA ULTRA $104 1 payment
  6. VISTASEAL $73 2 payments
  7. SURGICEL NU-KNIT $73 2 payments
  8. SURGIFLO Hemostatic Matrix $73 2 payments
  9. PERCLOT $41 1 payment
  10. SEPRAFILM $41 1 payment
  11. Other $124 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

115

Median for General Surgery: 59

Drug cost

$3,144

Median for General Surgery: $393

Branded share of claims

13%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 26 $2,221
Pantoprazole Sodium Generic 44 $617
Ondansetron Odt Ondansetron Brand 15 $169
Omeprazole Generic 11 $101
Oxycodone Hcl Generic 19 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$23,996

Medicare's payments for the services billed

Medicare patients

54

Average age 67

Services billed

143

38 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Depression 63%
Diabetes 59%
Heart failure 41%
Ischemic heart disease 30%
Atrial fibrillation 30%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obesity Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record